300204.SHE Staidson Beijing Biopharma
- Market cap
- CNY 9.32B
- P/E
- -
- P/B
- 4.50x
- ROE
- -3.5%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300204.SHE undervalued?
Graham numberThe Graham number of Staidson Beijing Biopharma cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Staidson Beijing Biopharma fundamental analysis
No fundamental analysis for Staidson Beijing Biopharma yet.
Staidson Beijing Biopharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product port…
Full company profileStaidson Beijing Biopharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Staidson Beijing Biopharma annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.40B | 1.39B | 806M | 661M | 425M | 584M | 549M | 364M | 325M | 220M | 196M |
| Gross Profit | 1.33B | 1.31B | 731M | 581M | 348M | 468M | 447M | 290M | 263M | 170M | 143M |
| Operating Income | 295M | 303M | 150M | 20.3M | -155M | -213M | -243M | -366M | -33.6M | -78.4M | -58.8M |
| EBITDA | 319M | 328M | 178M | 51.8M | -124M | -178M | -211M | -334M | -11.3M | -55.7M | -59.3M |
| Net Income | 257M | 263M | 134M | 27.3M | -133M | -137M | -197M | -399M | -145M | -77.8M | -70.0M |
| EPS | 0.54 | 0.55 | 0.28 | 0.06 | -0.28 | -0.29 | -0.41 | -0.84 | -0.30 | -0.16 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 2.35B | 2.63B | 2.77B | 1.86B | 1.86B | 1.83B | 1.67B | 1.33B | 1.15B | 1.27B | 2.36B |
| Total Liabilities | 432M | 419M | 314M | 227M | 269M | 276M | 315M | 312M | 233M | 459M | 368M |
| Shareholders' Equity | 1.90B | 2.21B | 2.46B | 1.64B | 1.59B | 1.55B | 1.35B | 1.02B | 929M | 821M | 2.01B |
| Cash & Short-term Investments | 350M | 401M | 365M | 628M | 602M | 466M | 265M | 85.2M | 53.9M | 124M | 556M |
| Total Debt | 60.0M | 3.57M | 3.51M | 3.64M | 55.8M | 7.63M | 29.0M | 41.0M | 30.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 213M | 274M | 165M | 44.3M | -115M | -162M | -176M | -227M | -63.7M | -126M | - |
| Capital Expenditure | 26.4M | 46.6M | 95.5M | 59.9M | 48.9M | 56.2M | 56.5M | 32.2M | 23.5M | 76.6M | 79.1M |
| Free Cash Flow | 186M | 227M | 69.6M | -15.6M | -163M | -218M | -232M | -260M | -87.2M | -202M | -156M |
| Ratios | |||||||||||
| ROE | 13.5% | 11.9% | 5.5% | 1.7% | -8.4% | -8.9% | -14.6% | -39.1% | -15.6% | -9.5% | -3.5% |
| ROA | 10.9% | 10.0% | 4.8% | 1.5% | -7.2% | -7.5% | -11.8% | -29.9% | -12.6% | -6.1% | -3.0% |
| Net Profit Margin | 18.3% | 19.0% | 16.6% | 4.1% | -31.3% | -23.5% | -35.9% | -109.5% | -44.6% | -35.3% | -35.6% |
| Debt to Equity | 0.03x | 0.00x | 0.00x | 0.00x | 0.04x | 0.00x | 0.02x | 0.04x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Staidson Beijing Biopharma dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 17, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.09M | 0.00 | - |
| 2024 | CNY 543K | 0.00 | - |
| 2023 | CNY 1.02M | 0.00 | - |
| 2022 | - | - | - |
| 2021 | CNY 320K | 0.00 | - |
| 2020 | CNY 855K | 0.00 | - |
| 2019 | CNY 314M | 0.69 | 1,151.0% |
| 2018 | CNY 119M | 0.25 | 89.0% |
| 2017 | CNY 85.7M | 0.18 | 32.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13.99594:10 on May 5, 2016.
Who owns Staidson Beijing Biopharma
- Insiders 37.58%
- Institutions 4.97%
- Public & others 57.45%
- Shares outstanding 541M
- Free float 299M
Staidson Beijing Biopharma company profile
- Company name
- Staidson Beijing Biopharma
- Ticker
- 300204.SHE
- ISIN
- CNE100001237
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 15, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 491
- Fiscal year end
- December
- Address
- No. 36, Jingha 2nd Road, Beijing, China, 100176
- Phone
- 86 10 6751 9888
- Website
- staidson.com
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C powder. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
Staidson Beijing Biopharma management
5- Mr. Wang ChaoGeneral Manager · born 1982
- Mr. Shicheng Li CPADeputy GM, Financial Director & Head of Accounting · born 1982
- Ms. Zhang LeiHuman Resources Director · born 1986
- Mr. Maorong YuSecretary of the Board & Deputy GM · born 1981
- Mr. Lei TienDirector of Production Center · born 1988